MIRA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -17.09%, SMA50 -21.41%, SMA200 -19.05%). The stock’s 14-day RSI is 22.64 (weak momentum), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -53.88% below its high and over 54.79% above its low. Average 10-day trading volume of 209.19 thousand shares is in line with the 3-month average of 204.43 thousand, indicating normal recent market interest.

MIRA Pharmaceuticals, Inc. has 19.07 million shares outstanding. The public float is 14.67 million shares, elevated short interest at 2.66% of float. This equals 388.88 thousand shares. The short ratio is 0.12 days. Institutional investors hold 6.52% of the float. Insiders own 22.37%.

MIRA Pharmaceuticals, Inc. generated EPS of -$1.52 over the past year. Five-year average earnings growth is -224.25%. MIRA Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 1375.0%. The prior quarter beat by 970.37%. Over the last six quarters, Apple has recorded several small beats. These include -22.22% in November 12, 2024.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) closed at $1.13 USD, losing -$0.08 (-6.61%) from the previous close of $1.21. The stock is currently mid-range between its 52-week high and low $0.73 and $2.45. With a market capitalization of about $47.32 million, MIRA Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.82). Key stats such as the average daily volume over the past year has been around 215.81 thousand shares, in line with its 52-week average. Headquartered in Baltimore, MD, MIRA Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Erez Aminov, the company employs approximately 2 people and listed since August 14, 2023. MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company.

MIRA Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

MIRA Pharmaceuticals, Inc. trades at a P/E ratio of -0.78, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.94 suggesting the stock is closer to book value. The P/FCF stands at -9.03, also above market averages.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares are flat -3.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MIRA Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.00, suggesting 1404.42% upside. Our AI forecast model points to short-term weakness (-16.81% over two weeks), a medium-term fall (-83.19% over three months), and a longer-term gain (1088.5% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MIRA Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -16.81%, with price expected at $0.94 by February 19, 2026, within a range of $0.89 to $0.99 3-Month Outlook: Projected fall of -83.19%, reaching $0.19 by May 06, 2026, with a range of $0.09 to $0.28. 1-Year Outlook: Projected gain of 1088.5%, with price at $13.43 by February 05, 2027, within a range of $12.31 to $15.59.